<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04342273</url>
  </required_header>
  <id_info>
    <org_study_id>6356-007</org_study_id>
    <nct_id>NCT04342273</nct_id>
  </id_info>
  <brief_title>A Through QT/QTc Study of KW-6356</brief_title>
  <official_title>A Through QT/QTc Study of KW-6356 in Japanese Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Kirin Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Kirin Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of multiple therapeutic and&#xD;
      supratherapeutic doses of KW-6356 on the QT interval corrected for heart rate in Japanese&#xD;
      healthy adults.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 31, 2020</start_date>
  <completion_date type="Actual">September 5, 2020</completion_date>
  <primary_completion_date type="Actual">September 5, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in QTc interval [QTcF] (ΔQTcF)</measure>
    <time_frame>Day 1 through Day 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in the HR</measure>
    <time_frame>Day 1 through Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in the QTc interval [QTcF]</measure>
    <time_frame>Day 1 through Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in the PR interval</measure>
    <time_frame>Day 1 through Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in the QRS interval</measure>
    <time_frame>Day 1 through Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placebo-corrected ΔQTcF</measure>
    <time_frame>Day 1 through Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placebo-corrected ΔHR</measure>
    <time_frame>Day 1 through Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placebo-corrected ΔPR interval</measure>
    <time_frame>Day 1 through Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placebo-corrected ΔQRS interval</measure>
    <time_frame>Day 1 through Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outliers in terms of category for HR</measure>
    <time_frame>Day 1 through Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outliers in terms of category for QTc interval (QTcF)</measure>
    <time_frame>Day 1 through Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outliers in terms of category for PR interval</measure>
    <time_frame>Day 1 through Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outliers in terms of category for QRS interval</measure>
    <time_frame>Day 1 through Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of morphological changes in T wave after administration of the investigational product</measure>
    <time_frame>Day 1 through Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of morphological changes in U wave after administration of the investigational product</measure>
    <time_frame>Day 1 through Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>Day 1 through Day 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of KW-6356</measure>
    <time_frame>Day 1 through Day 8, and Day 12</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">128</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>KW-6356 therapeutic dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KW-6356 supratherapeutic dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KW-6356</intervention_name>
    <description>KW-6356 will be administered once daily as therapeutic at Day 1 through Day 7</description>
    <arm_group_label>KW-6356 therapeutic dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KW-6356</intervention_name>
    <description>KW-6356 will be administered once daily as supratherapeutic dose at Day 1 through Day 7</description>
    <arm_group_label>KW-6356 supratherapeutic dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered once daily at Day 1 through Day 7</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>Placebo will be administered once daily at Day 1 through Day 6, followed by Moxifloxacin once daily at Day 7.</description>
    <arm_group_label>Moxifloxacin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects having issued written consent to this study at their own discretion&#xD;
&#xD;
          -  Men or women aged 20 to 54 years at the time of informed consent&#xD;
&#xD;
          -  Subjects with BMI ≥18.5 and &lt;25.0 at screening&#xD;
&#xD;
          -  In case of women of childbearing potential,* subjects who have agreed to use highly&#xD;
             effective and appropriate contraceptive methods from the time of informed consent to 4&#xD;
             weeks after the last dose of the investigational product or the index drug. Women of&#xD;
             childbearing potential must have a negative serum pregnancy test at screening&#xD;
&#xD;
          -  At screening and Day -2, subjects with resting pulse rate of ≥45 and &lt;100 bpm,&#xD;
             systolic blood pressure of ≥90 and &lt;140 mmHg, and diastolic blood pressure of ≥40 and&#xD;
             &lt;90 mmHg when measured in the supine position&#xD;
&#xD;
          -  Subjects whose standard 12-lead ECG data obtained at screening and Day -2 meet the&#xD;
             following criteria and show no clinically significant abnormalities as confirmed by&#xD;
             the investigator or subinvestigator Normal sinus rhythm: HR of ≥45 and ≤100 bpm QTc&#xD;
             interval (QTcF): ≤450 msec QRS interval: ≤120 msec (must be re-measured manually if&#xD;
             exceeding 120 msec) PR interval: ≤220 msec&#xD;
&#xD;
          -  Subjects whose potassium, sodium, calcium, and magnesium levels at screening are&#xD;
             within institutional normal limits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with any current disease requiring treatment&#xD;
&#xD;
          -  Subjects having drug allergy or its history&#xD;
&#xD;
          -  Subjects having psychiatric disease or its history&#xD;
&#xD;
          -  Positive results for any of the following infection-related items examined at&#xD;
             screening: hepatitis B surface (HBs) antigen, HBs antibody, hepatitis B core (HBc)&#xD;
             antibody, hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV)&#xD;
             antigen/antibody, human T-lymphotropic virus (HTLV)-1 antibody, rapid plasma reagin&#xD;
             (RPR) test, or Treponema pallidum (TP) antibody&#xD;
&#xD;
          -  Subjects being alcohol- or drug-dependent or having a positive result for any of the&#xD;
             drug abuse test items&#xD;
&#xD;
          -  Subjects previously or concurrently having any of the following diseases or subjects&#xD;
             with a family history of any of the following diseases:&#xD;
&#xD;
        Hypokalemia, hypocalcemia, and/or long QT syndrome Risk factors for torsade de pointes such&#xD;
        as cardiac failure, cardiomyopathy, and a family history of long QT syndrome Sick sinus&#xD;
        syndrome, second- or third-degree atrioventricular block, myocardial infarction, pulmonary&#xD;
        congestion, cardiac arrhythmia, QT interval prolongation, or atrioventricular conduction&#xD;
        disturbance Repeated or frequent syncope or vasovagal attack Hypertension, angina pectoris,&#xD;
        bradycardia, or severe peripheral arterial circulatory disorder&#xD;
&#xD;
          -  Subjects categorized as patients listed in the warnings or contraindications section&#xD;
             of the package insert of moxifloxacin hydrochloride&#xD;
&#xD;
          -  Subjects unable to be compliant with Specified &quot;Concomitant Medication and Concomitant&#xD;
             Therapy&quot; and &quot;Instruction for Subjects&quot;&#xD;
&#xD;
          -  Subjects having participated in a clinical study of a pharmaceutical product or a&#xD;
             medical device or any equivalent study and used the investigational product or the&#xD;
             unapproved medical device within 4 months prior to administration of the&#xD;
             investigational product&#xD;
&#xD;
          -  Subjects having used any drug within 2 weeks prior to administration of the&#xD;
             investigational product&#xD;
&#xD;
          -  Subjects having consumed grapefruit or any food or beverage containing St John's wort&#xD;
             within 1 week prior to administration of the investigational product&#xD;
&#xD;
          -  Subjects having smoked or used smoking cessation agents within 4 weeks prior to&#xD;
             administration of the investigational product&#xD;
&#xD;
          -  Subjects categorized as &quot;yes&quot; to &quot;active suicidal ideation with some intent to act,&#xD;
             without specific plan&quot; or &quot;active suicidal ideation with specific plan and intent&quot; on&#xD;
             the Columbia-Suicide Severity Rating Scale assessed on Day -2 or subjects with a&#xD;
             history of or currently observed suicidal behavior&#xD;
&#xD;
          -  Subjects having undergone ≥400 mL of blood collection within 12 weeks prior to&#xD;
             administration of the investigational product or ≥200 mL of blood collection within 4&#xD;
             weeks prior to administration of the investigational product for blood donation or in&#xD;
             a clinical trial, etc. or subjects having undergone blood collection for pheresis&#xD;
             donation within 2 weeks prior to administration of the investigational product&#xD;
&#xD;
          -  Subjects having issued no consent to adoption of any appropriate contraceptive method&#xD;
             during the period from day of informed consent to 4 weeks after the final&#xD;
             administration of the investigational product or the index drug for women of&#xD;
             childbearing potential and during the period from start day of study treatment to 12&#xD;
             weeks after the final administration of the investigational product or the index drug&#xD;
             for men of reproductive potential. The appropriate contraceptive method&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>54 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical Co. LTA Sumida Hospital</name>
      <address>
        <city>Sumida-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Co. LTA Fukuoka Mirai Hospital Clinical Research Center</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 8, 2020</study_first_submitted>
  <study_first_submitted_qc>April 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2020</study_first_posted>
  <last_update_submitted>September 16, 2020</last_update_submitted>
  <last_update_submitted_qc>September 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

